Working with the World Bank and the Union for International Cancer Control, Bristol Myers Squibb is one of 22 biopharmaceutical companies involved in the collaboration.
“Our focus on patients is unwavering,” said Bristol Myers Squibb CEO Giovanni Caforio, M.D. “Working together with multilateral organizations and our partners in the pharmaceutical industry, we aim to improve the prevention, care and treatment of non-communicable diseases like cancer through innovative medicines.”